Clinical Data Needed For Some Digital Mammography 510(k)s, Panel Says
This article was originally published in The Gray Sheet
FDA should require some clinical data in 510(k) or de novo 510(k) submissions for new full-field digital mammography devices that substantially change or improve the perception of breast cancer images when compared with prior models, an FDA advisory panel recommended Nov. 17
You may also be interested in...
Digital mammography systems are on the verge of being downclassified to 510(k) status, but imaging firms say the clinical trial requirements proposed in FDA's draft "special controls" guidance for the systems are costly, unnecessary and overly burdensome
Digital mammography is more accurate than traditional film mammography in women under 50 and women with dense breasts, according to a study slated to appear in the Oct. 27 New England Journal of Medicine
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.